Suppr超能文献

妊娠和围生期结局中的高血压和降压药物。

Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes.

机构信息

Department of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

出版信息

Am J Obstet Gynecol. 2013 Apr;208(4):301.e1-6. doi: 10.1016/j.ajog.2012.11.011. Epub 2012 Nov 15.

Abstract

OBJECTIVE

Despite high rates of hypertension in pregnancy, the effects of hypertension have not been separated appropriately from the effects of the medications that are used. We evaluated the safety of exposure to antihypertensive medications during pregnancy, while accounting for disease effects.

STUDY DESIGN

A population-based retrospective cohort study was performed that compared all pregnancies of women with hypertension who were either exposed or unexposed to antihypertensive medications. A computerized database of the medications that were dispensed to pregnant women from 1998-2008 was linked with computerized databases that contained maternal and infant hospitalization records from the district hospital during the same period.

RESULTS

During the study period, 100,029 deliveries occurred; of those, 1964 pregnant women experienced chronic hypertension, and 620 neonates (0.6%) were exposed to at least 1 antihypertensive medication (methyldopa or atenolol) during pregnancy. A higher rate of intrauterine growth restriction (7.2% vs 2.1%, respectively; adjusted odds ratio [OR], 4.37; 95% confidence interval [CI], 3.00-6.36; P < .001), small for gestational age (3% vs 1.7%, respectively; adjusted OR, 2.23; 95% CI, 1.27-3.92; P = .005), and preterm deliveries (<37 weeks, 22.9% vs 8.0%, respectively; adjusted OR, 3.69; 95% CI, 2.90-4.69; P < .001) were noted among the pregnancies of women who were exposed to antihypertensive medications during the third trimester. Importantly, a similar association was detected when we compared women with chronic hypertension who were not treated during pregnancy (n = 1074) to women who had no chronic hypertension and who were unexposed to antihypertensive medications (n = 97,820).

CONCLUSION

Chronic hypertension with or without treatment during pregnancy is an independent and significant risk factor for adverse perinatal outcomes such as intrauterine growth restriction, small for gestational age, and preterm delivery.

摘要

目的

尽管妊娠高血压的发病率很高,但高血压的影响尚未与所用药物的影响适当区分开来。我们评估了妊娠期间暴露于抗高血压药物的安全性,同时考虑了疾病的影响。

研究设计

进行了一项基于人群的回顾性队列研究,比较了患有高血压的孕妇中暴露于和未暴露于抗高血压药物的所有妊娠。1998 年至 2008 年期间,将向孕妇发放的药物的计算机数据库与同一时期地区医院产妇和婴儿住院记录的计算机数据库相链接。

结果

在研究期间,共发生 100029 例分娩;其中,1964 名孕妇患有慢性高血压,620 名新生儿(0.6%)在妊娠期间至少使用了 1 种抗高血压药物(甲基多巴或阿替洛尔)。宫内生长受限的发生率更高(分别为 7.2%和 2.1%;调整后的比值比[OR],4.37;95%置信区间[CI],3.00-6.36;P<0.001)、小于胎龄儿(分别为 3%和 1.7%;调整后的 OR,2.23;95% CI,1.27-3.92;P=0.005)和早产(<37 周,分别为 22.9%和 8.0%;调整后的 OR,3.69;95% CI,2.90-4.69;P<0.001)在妊娠期间暴露于抗高血压药物的孕妇中更为常见。重要的是,当我们将未接受妊娠期间治疗的慢性高血压孕妇(n=1074)与无慢性高血压且未接受抗高血压药物治疗的孕妇(n=97820)进行比较时,也发现了类似的关联。

结论

妊娠期间患有或未治疗的慢性高血压是宫内生长受限、小于胎龄儿和早产等不良围产结局的独立且重要的危险因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验